- Residency - New York University School of Medicine (2015-2019), Urology
- Internship - New York University School of Medicine (2014-2015), General Surgery
- Medical School - NYU School of Medicine (2005-2014)
Xiaosong Meng, M.D., Ph.D.
- Dedman Family Scholar in Clinical Care
- Prostate Cancer
- Genitourinary Cancer
Dr. Meng earned his medical degree and doctoral degree in cell and molecular biology at New York University, where he also completed a residency in urology. He received advanced training in urologic oncology through a fellowship at UT Southwestern.
He joined the UT Southwestern faculty in 2021.
Dr. Meng's clinical interests include prostate cancer and focal therapy for prostate cancer, kidney cancer, testicular cancer, and bladder cancer.
The author of numerous scholarly articles and presentations, Dr. Meng’s research focuses on better understanding the molecular mechanisms that underlie the immune response in order to determine which prostate cancer patients are best managed by focal therapy.
He also researches ways to improve diagnosis and treatment of kidney and prostate cancer, the metabolomics of genitourinary malignancies, and focal or partial treatment choices for localized prostate cancer.
- American Urologic Association
- Young Urologic Oncologists Section, Society of Urologic Oncology
- Alpha Omega Alpha Honor Medical Society
- 1st Place in Clinical Research 2019, American Urological Association - New York Section, Ferdinand C. Valentine Medal & Resident Essay Meeting
- Coffey-Krane Prize 2018, BJU International
- Best Poster Award 2018, American Urological Association Annual Meeting
- 2nd Place in Clinical Research 2017, American Urological Association – New York Section, Ferdinand C. Valentine Medal & Resident Essay Meeting
- Best Poster Award 2016, American Urological Association Annual Meeting
- Honorable Mention 2017, American Urological Association – New York Section, Ferdinand C. Valentine Medal & Resident Essay Meeting
- 3rd Place Poster Award 2014, Society of Urologic Oncology Annual Meeting
- Samuel and Edgar H. Soifer Memorial Award for Excellence in Urology 2014, New York University
- Alpha Omega Alpha Honor Medical Society 2013
Assembly and maintenance of nodes of ranvier rely on distinct sources of proteins and targeting mechanisms.
Zhang Y, Bekku Y, Dzhashiashvili Y, Armenti S, Meng X, Sasaki Y, Milbrandt J, Salzer JL, Neuron 2012 Jan 73 1 92-107
Real-World Application of Pre-orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR, Abe D, Wong D, Singla N, Savelyeva A, Chertack N, Woldu SL, Lotan Y, Mauck R, Ouyang D, Meng X, Lewis CM, Majmudar K, Jia L, Kapur P, Xu L, Frazier AL, Margulis V, Strand DW, Coleman N, Murray MJ, Amatruda JF, Lafin JT, Bagrodia A, The Journal of urology 2020 Aug 101097JU0000000000001337
Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.
Mendhiratta N, Meng X, Rosenkrantz AB, Wysock JS, Fenstermaker M, Huang R, Deng FM, Melamed J, Zhou M, Huang WC, Lepor H, Taneja SS, Urology 2015 Dec 86 6 1192-8
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.
Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, Taneja SS, The Journal of urology 2014 Sep 192 3 648-58
Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
Mendhiratta N, Rosenkrantz AB, Meng X, Wysock JS, Fenstermaker M, Huang R, Deng FM, Melamed J, Zhou M, Huang WC, Lepor H, Taneja SS, The Journal of urology 2015 Dec 194 6 1601-6
Using multiparametric MRI to 'personalize' biopsy for men.
Mendhiratta N, Meng X, Taneja SS, Current opinion in urology 2015 Nov 25 6 498-503
Discordance Between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma.
Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB The Journal of urology 2018 Feb
Tumor location does not limit percutaneous treatment of small renal masses with microwave ablation.
Meng X, Ghandour R, Margulis V, Annals of translational medicine 2019 Sep 7 Suppl 6 S231
Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.
Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A, Cancer 2020 Aug
Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence after Nephrectomy for Renal Cell Carcinoma.
Ghandour R, Miranda AF, Singla N, Meng X, Enikeev D, Woldu S, Bagrodia A, Cadeddu J, Gahan J, Margulis V, Urology 2020 Aug
The 4.1B cytoskeletal protein regulates the domain organization and sheath thickness of myelinated axons.
Einheber S, Meng X, Rubin M, Lam I, Mohandas N, An X, Shrager P, Kissil J, Maurel P, Salzer JL Glia 2013 Feb 61 2 240-53
Meng X, Taneja SS, The Journal of urology 2016 08 196 2 365
Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
Wysock JS, Mendhiratta N, Zattoni F, Meng X, Bjurlin M, Huang WC, Lepor H, Rosenkrantz AB, Taneja SS, BJU international 2016 10 118 4 515-20
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Domènech-Estévez E, Baloui H, Meng X, Zhang Y, Deinhardt K, Dupree JL, Einheber S, Chrast R, Salzer JL, The Journal of neuroscience : the official journal of the Society for Neuroscience 2016 Apr 36 16 4506-21
Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.
Fenstermaker M, Mendhiratta N, Bjurlin MA, Meng X, Rosenkrantz AB, Huang R, Deng FM, Zhou M, Huang WC, Lepor H, Taneja SS Urology 2016 Aug
Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy.
Rosenkrantz AB, Meng X, Ream JM, Babb JS, Deng FM, Rusinek H, Huang WC, Lepor H, Taneja SS, Journal of magnetic resonance imaging : JMRI 2016 Feb 43 2 325-32
Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS, European urology 2016 Mar 69 3 512-7
Role of prostate magnetic resonance imaging in active surveillance.
Meng X, Rosenkrantz AB, Taneja SS, Translational andrology and urology 2017 Jun 6 3 444-452
Discriminative Ability of Commonly Used Indexes to Predict Adverse Outcomes After Radical Cystectomy: Comparison of Demographic Data, American Society of Anesthesiologists, Modified Charlson Comorbidity Index, and Modified Frailty Index.
Meng X, Press B, Renson A, Wysock JS, Taneja SS, Huang WC, Bjurlin MA, Clinical genitourinary cancer 2018 08 16 4 e843-e850
Necl-4/Cadm4 recruits Par-3 to the Schwann cell adaxonal membrane.
Meng X, Maurel P, Lam I, Heffernan C, Stiffler MA, McBeath G, Salzer JL, Glia 2019 05 67 5 884-895
Different models for prediction of radical cystectomy postoperative complications and care pathways.
Taylor J, Meng X, Renson A, Smith AB, Wysock JS, Taneja SS, Huang WC, Bjurlin MA, Therapeutic advances in urology 2019 Jan-Dec 11 1756287219875587
High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma.
Meng X, Chao B, Vijay V, Silver H, Margolin EJ, Balar A, Taneja SS, Shah O, Bjurlin MA, Anderson CB, Huang WC, Urology 2019 Jul 129 146-152
Advancements in the clinical management of upper tract urothelial carcinoma.
Taylor J, Meng X, Ghandour R, Margulis V, Expert review of anticancer therapy 2019 Nov
Critical treatment choices for patients with platinum-refractory urothelial carcinoma.
Lotan Y, Meng X, The Lancet. Oncology 2019 Nov
Oncologic outcomes of radical nephroureterectomy (RNU).
Kenigsberg AP, Meng X, Ghandour R, Margulis V, Translational andrology and urology 2020 Aug 9 4 1841-1852
Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
Ghandour RA, Kusin S, Wong D, Meng X, Singla N, Freifeld Y, Bagrodia A, Margulis V, Sagalowsky A, Lotan Y, Woldu SL, Urologic oncology 2020 Jul
Prospective evaluation of blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, Bagrodia A, Margulis V, Woldu S, Daneshmand S, BJU international 2020 Jul
Robotic Nephroureterectomy vs. Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically.
Kenigsberg A, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, Lotan Y, Woldu S, Margulis V, Journal of endourology 2020 Oct
Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
Feuer Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, Moore CM, Huang R, Deng FM, Lepor H, Wysock JS, Huang WC, Taneja SS, The Journal of urology 2021 03 205 3 740-747
Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
Meng X, Chao B, Chen F, Huang R, Taneja SS, Deng FM, The Journal of urology 2021 Mar 205 3 748-754
The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years.
Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin MA, Huang WC, Lepor H, Taneja SS, The Journal of urology 2018 11 200 5 1022-1029
- Assembly and maintenance of nodes of ranvier rely on distinct sources of proteins and targeting mechanisms.
- Diagnosis and treatment of kidney and prostate cancer
- Focal therapy for prostate cancer
- Prostate Cancer
- Genitourinary Cancer
- Kidney Cancer
- Testicular Cancer
- Bladder Cancer